查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1464769

慢性发炎去髓鞘化多发性神经病变市场：按治疗、诊断和最终用户分类 - 全球预测 2024-2030

Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment (Corticosteroids, Intravenous Immunoglobulin (IVIG), Physiotherapy), Diagnosis (Blood & Urine Tests, Electrodiagnostic Testing, Lumbar Puncture), End-Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年慢性发炎去髓鞘化神经病变市场规模为23.5亿美元，2024年达24.9亿美元，2030年达34.9亿美元，复合年增长率为5.81%。

慢性发炎去髓鞘化多发性神经病变 (CIDP) 是一种神经肌肉或自体免疫疾病，分类为腿部和手臂感觉功能受损。此疾病是由于免疫系统错误地攻击神经的保护膜（也称为髓鞘）引起的。结果，神经讯号传导减慢，导致肌肉无力、反射减弱和感觉障碍。 CIDP是一种慢性疾病，也是神经病学中最重要的疾病之一，因为它对患者的生活品质有重大影响。快速识别和适当的治疗性介入对于控制症状和改善结果至关重要，这凸显了持续研究和开发针对这种衰弱性疾病的治疗方法的重要性。对神经系统疾病的日益关注以及政府支持这些疾病治疗的积极努力正在推动对 CIDP 治疗的需求。然而，与 CIDP 相关的高成本对製造商和最终用户来说是一个重大挑战。公司不断致力于研发 (R&D)，推出新药以在这个时代保持敏捷。此外，CIDP 诊断和治疗方面的技术创新正在改善患者的治疗效果并推动需求。创新研发包括开发更有效、侵入性更小的治疗方法、开髮用于早期准确检测的新型诊断工具以及探索CIDP的遗传基础以发现新的治疗标靶等。

主要市场统计
基准年[2023] 23.5亿美元
预测年份 [2024] 24.9亿美元
预测年份 [2030] 34.9亿美元
复合年增长率（%） 5.81%

透过增加静脉注射人类免疫球蛋白 G 治疗 CIDP 的使用来改善患者预后

慢性发炎去髓鞘化多发性神经病变 (CIDP) 的治疗包括一种整体方法，旨在抑制不适当的免疫反应，同时改善患者的生活品质。治疗通讯协定的第一线是静脉注射静脉注射（IVIG），它提供调节免疫系统功能的抗体。泼尼松等皮质类固醇可以减轻发炎并调节免疫系统活力，同样重要。血浆去除术是一种替代策略，涉及血液净化，以去除对这些治疗没有反应的患者的有害抗体。物理治疗在CIDP的综合治疗中起着至关重要的作用，其目的是维持和提高肌肉力量、灵活性和可操作性。

最终使用者：扩大 CIDP 在医院和诊所治疗的可能性，使有效的治疗方法更广泛地获得。

医院已成为初步诊断和治疗的重要设施，提供包括静脉注射免疫球蛋白（IVIg）治疗在内的全面护理，这需要专门的医疗设备和专业知识。专科诊所由具有 CIDP 深入知识的专业人员提供持续管理和专业治疗，提供强化治疗方法。居家照护越来越受到人们的关注，以保持护理的连续性，特别是在包括皮下免疫球蛋白 (SCIg) 治疗在内的长期治疗中。这些设定中的每一种都提供不同的益处并满足 CIDP 患者群体的特定需求，确保广泛获得有效的治疗方法。

区域洞察

在美洲，特别是在美国和加拿大，对 CIDP 的认识和诊断不断增加，对有效治疗的需求也在增加。以患者为中心的医疗保健系统和高购买力推动了客户对创新治疗方法的强烈购买行为。庞大的研发投资和有利的医疗政策正在支持 CIDP 市场的成长。 FDA 最近核准了 CIDP 治疗，证实了该地区对解决这种使人衰弱的疾病的承诺。另一方面，欧盟 (EU) 国家在 CIDP 认知、诊断和治疗取得方面存在不同的情况。欧盟的医疗体系优先考虑公平获取，包括 CIDP 在内的不同国家采取了不同的模式来支持罕见疾病治疗。最近的欧盟范围内的倡议着重于加强研究、简化监管途径和促进跨境医疗合作，旨在改善整个欧洲大陆的病患治疗效果。由于医疗保健支出的增加和诊断能力的提高，中国、日本和印度等亚太国家在 CIDP 市场中正在迅速发展。日本是一个医疗保健技术先进且注重研究的地区，大量的专利和临床试验证明了这一点。中国和印度因其人口众多以及对包括 CIDP 在内的自体免疫疾病的认识不断提高而成为重要市场。

FPNV定位矩阵

FPNV定位矩阵对于评估慢性发炎去髓鞘化多发性神经病变市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对发炎去髓鞘化多发性神经病变市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.慢性发炎去髓鞘化多发性神经病变市场的市场规模与预测是多少？

2.在慢性发炎去髓鞘化神经病变市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.慢性发炎去髓鞘化多发性神经病变市场的技术趋势和法规结构是什么？

4.发炎去髓鞘化神经病变市场主要供应商的市场占有率为何？

5.进入慢性发炎去髓鞘化多发性神经病变市场的合适型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 自体免疫和神经系统疾病在全世界日益受到关注
      • 扩大罕见疾病的医疗保健费用和保险范围
      • 政府对 CIDP 治疗的有利倡议和核准
    • 抑制因素
      • CIDP 治疗相关的高费用
    • 机会
      • 正在进行的研究旨在了解 CIDP 的病理并开发新的治疗方法
      • CIDP 诊断和治疗的持续创新改善了患者的治疗效果
    • 任务
      • 由于症状与其他神经肌肉疾病相似而误诊或延迟诊断
  • 市场区隔分析
    • 治疗：在 CIDP 治疗中增加人类静脉注射免疫球蛋白 G 的使用，以改善患者预后
    • 最终用途：扩大 CIDP 治疗在医院和诊所的可用性，以确保更广泛地获得有效的治疗方法
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章慢性发炎去髓鞘化多发性神经病变市场的治疗

  • 皮质类固醇
  • 静脉注射免疫球蛋白 (IVIG)
  • 物理治疗
  • 血浆置换

第七章慢性发炎去髓鞘化多发性神经病变诊断市场

  • 血液和尿液检查
  • 电诊断测试
  • 腰椎穿刺

第八章慢性发炎去髓鞘化多发性神经病变市场：依最终用途分类

  • 家庭护理设置
  • 医院
  • 专科诊所

第九章美洲慢性发炎性脱髓鞘去髓鞘化神经病变市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区发炎去髓鞘化多发性神经病变市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的慢性发炎去髓鞘化多发性神经病变市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 武田的 HYQVIA 获欧盟委员会核准作为 CIDP 患者的维持治疗
    • 武田製药的 HYQVIA 获得 FDA核准用于治疗 CIDP
    • 再鼎医药艾法莫德注射（皮下注射）在中国获得针对慢性发炎去髓鞘化多发性神经病变患者的突破性治疗认定
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-F97DD5A7D581

[187 Pages Report] The Chronic Inflammatory Demyelinating Polyneuropathy Market size was estimated at USD 2.35 billion in 2023 and expected to reach USD 2.49 billion in 2024, at a CAGR 5.81% to reach USD 3.49 billion by 2030.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neuromuscular or autoimmune disorder categorized by impaired sensory function in the legs and arms. The condition stems from the immune system mistakenly attacking the protective covering of the nerves, also known as the myelin sheath. This leads to slow nerve signal conduction, causing muscle weakness, reflex loss, and sensory problems. CIDP is paramount in neurology due to its chronic nature and significant impact on patient's quality of life. Rapid identification and appropriate therapeutic intervention are crucial in managing the symptoms and improving outcomes, highlighting the importance of ongoing research and development in treatments targeting this debilitating disorder. The rising concerns about neurological disorders and favorable government initiatives to support the treatment of these disorders propel the demand for CIDP treatment. However, the high cost associated with the CIDP is a significant challenge for the manufacturers and end users. Companies are constantly working towards research and development (R&D) and introducing novel drugs to remain agile within the landscape. Moreover, the Innovations in diagnostics and therapeutics for CIDP improve patient outcomes, thereby driving demand. Innovation and research include the development of more effective and less invasive treatment methods, novel diagnostic tools for early and accurate detection, and exploring the genetic basis of CIDP to uncover new therapeutic targets.

KEY MARKET STATISTICS
Base Year [2023] USD 2.35 billion
Estimated Year [2024] USD 2.49 billion
Forecast Year [2030] USD 3.49 billion
CAGR (%) 5.81%

Treatment: Increasing usage of human intravenous immunoglobulin G in CIDP treatment to cater better patient outcomes

Chronic inflammatory demyelinating polyneuropathy (CIDP) management encompasses a holistic approach designed to dampen the improper immune reaction while enhancing the patient's quality of life. At the forefront of treatment protocols is administering intravenous immunoglobulin (IVIG), which supplies antibodies to adjust the immune system's functionality. Corticosteroids such as prednisone, which alleviate inflammation and modulate the immune system's vigor, are equally critical. Plasmapheresis represents an alternative strategy involving blood purification to eliminate deleterious antibodies for patients unresponsive to these treatments. Integral to the treatment regimen, physiotherapy aims to preserve and improve muscle strength, suppleness, and operational capacity, thereby playing an indispensable role in the comprehensive care approach for CIDP.

End-Use: Widening availability of CIDP treatment in hospitals and clinics to ensure broader accessibility to effective treatment regimens

Hospitals emerge as key facilities for initial diagnosis and treatment, providing comprehensive care, including intravenous immunoglobulin (IVIg) therapy, which demands specialized medical equipment and expertise. Specialty clinics offer a focused approach, catering to ongoing management and specialized treatments with professionals with in-depth knowledge of CIDP. Homecare settings are gaining prominence in maintaining the continuum of care, especially for long-term treatments, including subcutaneous immunoglobulin (SCIg) therapy, allowing patients comfort and convenience while minimizing hospital visits. Each of these settings offers distinct advantages and caters to the specific needs of the CIDP patient population, ensuring broader accessibility to effective treatment regimens.

Regional Insights

In the Americas, particularly the United States and Canada, there is a growing awareness and diagnosis rate of CIDP, driving demand for effective treatments. Patient-centric healthcare systems and high purchasing power produce strong customer purchasing behavior for innovative therapies. Significant R&D investments, coupled with favorable healthcare policies, support the growth of the CIDP market. Recent FDA approvals for CIDP treatments underscore the region's commitment to addressing this debilitating condition. On the other hand, European Union (EU) countries show a diverse landscape regarding CIDP awareness, diagnosis, and treatment access. Healthcare systems in the EU prioritize equitable access, with various countries adopting different models, including CIDP, to support rare disease treatments. Recent EU-wide initiatives focus on enhancing research, streamlining regulatory pathways, and fostering cross-border healthcare cooperation, aiming to improve patient outcomes across the continent. Asia Pacific countries such as China, Japan, and India are rapidly evolving in the CIDP market space, driven by increasing healthcare spending and improving diagnostic capabilities. Japan is in the region with advanced healthcare technologies and a strong focus on research, demonstrated by the high volume of patents and clinical trials. China and India are significant markets due to their large populations and growing awareness of autoimmune diseases, including CIDP.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Chronic Inflammatory Demyelinating Polyneuropathy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Chronic Inflammatory Demyelinating Polyneuropathy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Chronic Inflammatory Demyelinating Polyneuropathy Market, highlighting leading vendors and their innovative profiles. These include Avalon Pharma Pvt Ltd., Baxter International, Inc., Biotest AG, CSL Limited, F. Hoffmann-La Roche Ltd., Green Cross Corporation, Grifols, S.A., Johnson & Johnson Services, Inc., Kedrion Biopharma, Lee BioSolutions, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Viatris Inc., and Zai Lab Limited.

Market Segmentation & Coverage

This research report categorizes the Chronic Inflammatory Demyelinating Polyneuropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Corticosteroids
    • Intravenous Immunoglobulin (IVIG)
    • Physiotherapy
    • Plasmapheresis
  • Diagnosis
    • Blood & Urine Tests
    • Electrodiagnostic Testing
    • Lumbar Puncture
  • End-Use
    • Homecare Settings
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Chronic Inflammatory Demyelinating Polyneuropathy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Chronic Inflammatory Demyelinating Polyneuropathy Market?

3. What are the technology trends and regulatory frameworks in the Chronic Inflammatory Demyelinating Polyneuropathy Market?

4. What is the market share of the leading vendors in the Chronic Inflammatory Demyelinating Polyneuropathy Market?

5. Which modes and strategic moves are suitable for entering the Chronic Inflammatory Demyelinating Polyneuropathy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing concerns for autoimmune and neurological disorders worldwide
      • 5.1.1.2. Higher healthcare expenditure and insurance coverage for rare diseases
      • 5.1.1.3. Favorable government initiatives and approvals for CIDP treatment
    • 5.1.2. Restraints
      • 5.1.2.1. The high cost associated with CIDP treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research into understanding the pathophysiology of CIDP and the development of new treatments
      • 5.1.3.2. Continuous innovations in diagnostics and therapeutics for CIDP to improve patient outcomes
    • 5.1.4. Challenges
      • 5.1.4.1. Misdiagnosis or delayed diagnosis due to symptom similarity with other neuromuscular disorders
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Increasing usage of human intravenous immunoglobulin G in CIDP treatment to cater better patient outcomes
    • 5.2.2. End-Use: Widening availability of CIDP treatment in hospitals and clinics to ensure broader accessibility to effective treatment regimens
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment

  • 6.1. Introduction
  • 6.2. Corticosteroids
  • 6.3. Intravenous Immunoglobulin (IVIG)
  • 6.4. Physiotherapy
  • 6.5. Plasmapheresis

7. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Diagnosis

  • 7.1. Introduction
  • 7.2. Blood & Urine Tests
  • 7.3. Electrodiagnostic Testing
  • 7.4. Lumbar Puncture

8. Chronic Inflammatory Demyelinating Polyneuropathy Market, by End-Use

  • 8.1. Introduction
  • 8.2. Homecare Settings
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Chronic Inflammatory Demyelinating Polyneuropathy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Takeda's HYQVIA Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • 12.3.2. Takeda's HYQVIA Wins FDA Approval for CIDP Therapy
    • 12.3.3. Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET DYNAMICS
  • FIGURE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN (IVIG), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN (IVIG), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY BLOOD & URINE TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY BLOOD & URINE TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ELECTRODIAGNOSTIC TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ELECTRODIAGNOSTIC TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY LUMBAR PUNCTURE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY LUMBAR PUNCTURE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 57. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 58. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 63. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 64. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 71. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 72. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 86. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 91. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 92. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 97. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 98. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 103. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 104. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 109. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 110. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 115. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 116. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 122. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 127. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 128. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 134. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 139. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 140. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 145. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 146. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 151. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 152. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 165. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 166. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 171. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 172. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 177. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 178. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 183. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 184. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 189. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 190. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 195. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 196. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 201. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 202. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 208. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 213. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 214. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 219. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 220. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 225. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 226. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 231. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 232. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 237. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 238. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 244. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 255. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 256. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 261. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 262. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 268. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET S